Volume and duration of mensturation, Leiomyoma of uterus, size. Irregular menstruation, Leiomyoma of uterus, unspecified, Excessive and frequent mensturation with regular or irregular cycle
Conditions
Interventions
Intervention 1: The patients in case group will receive vitamin D pearl (brand name: Vitin-D 50000IU, manufactured by Zahravi pharmaceutical company, Iran)one per week for eight weeks, after which if
Treatment - Drugs
Placebo
Patients in control group will receive placebo pearl (manufactured by Zahravi pharmaceutical company, Iran) in similar route to intervention group for 8 weeks and followed without any additional inter
The patients in case group will receive vitamin D pearl (brand name: Vitin-D 50000IU, manufactured by Zahravi pharmaceutical company, Iran)one per week for eight weeks, after which if the levels of vi
Sponsors
Vice Chancellor for Research and Technology, Semnan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 20 and 45 years, having one or more uterine fibroids, the largest be 3 cm based on ultrasound, vitamin D and 25-hydroxyvitamin D concentrations lower than 75 nmol per liter or 30 ng/ml. Exclusion criteria: Leiomyoma with acute symptoms which requiring to immediate surgical intervention, liver or kidney disorders, cancer of the uterus, cervix and ovarian, adnexal mass, endometrial lesions such as polyps on ultrasound, use of hormonal therapy in the last three months, pregnancy, lactation or the desire to become pregnant during the study period, delivery within the last six months, uterine myoma in size more than 12 cm, the size of the uterine leiomyoma more than 20 weeks, history of gastrointestinal problems, especially malabsorption syndrome.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size of Uterine Liomyoma. Timepoint: 4 months after intervention. Method of measurement: Sonography study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Menstrual bleeding and related symptoms. Timepoint: 2, 3 and 4 months after intervention. Method of measurement: Pictorial Blood Loss Assessment Chart (PBAC) and Visual analog scale (VAS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mahboobeh Saghafi
Semnan University of Medical Sciences
Outcome results
None listed